The following video is part of our "Motley Fool Conversations" series, in which health-care editor and analyst David Williamson and consumer goods editor and analyst Austin Smith discuss topics across the investing world.
In this edition, David and Austin catch up on popular biotech Cell Therapeutics. The company has seen huge share price swings recently, first down 20% after pulling Pixuvri's application from the FDA before an advisory panel could weigh in, and then up a similar amount after a European advisory panel recommended approval. Find out what these events really mean for the company and for investors.
Austin Smith has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.